The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of KRAS and BRAF mutations with progression-free survival (PFS) with second-line FOLFIRI +/- regorafenib in metastatic colorectal cancer (mCRC).
 
Federico Innocenti
No Relationships to Disclose
 
Sara R. Selitsky
No Relationships to Disclose
 
Joel S. Parker
Consulting or Advisory Role - NanoString Technologies; NanoString Technologies; NanoString Technologies; NanoString Technologies
Patents, Royalties, Other Intellectual Property - Joel Parker has authored patents related to the PAM50 algorithm which are licensed to Nanostring Technologies.; Joel Parker has authored patents related to the PAM50 algorithm which are licensed to Nanostring Technologies.; Joel Parker has authored patents related to the PAM50 algorithm which are licensed to Nanostring Technologies.; Joel Parker has authored patents related to the PAM50 algorithm which are licensed to Nanostring Technologies.
 
James Todd Auman
No Relationships to Disclose
 
Kelli Hammond
No Relationships to Disclose
 
Sushant A. Patil
No Relationships to Disclose
 
Hanna Kelly Sanoff
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst)
 
Michael Sangmin Lee
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche